Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial compared two treatments — anetumab ravtansine (the experimental drug) and vinorelbine (an existing chemotherapy) — in people with a type of cancer called malignant pleural mesothelioma, a cancer affecting the lining of the lungs. A total of 166 people were assigned to the anetumab ravtansine group and 82 to the vinorelbine group. The trial's main goal was to measure how long participants went without their disease getting worse (called progression-free survival), and a number of secondary goals were also tracked, including how long participants lived overall, how many saw their tumour shrink, and how long any shrinkage lasted. The reported data shows that, for the main measure — time until the disease progressed or the person died — the anetumab ravtansine group had a reported median (the midpoint value for the group) of 4.3 months, compared with 4.5 months for the vinorelbine group. For overall survival (time from the start of the trial until death from any cause), the reported median was 9.5 months in the anetumab ravtansine group and 11.6 months in the vinorelbine group. Regarding tumour response, about 8.4% of participants in the anetumab ravtansine group and 6.1% in the vinorelbine group had their tumour shrink meaningfully. The reported data shows that disease was kept stable or better (either shrinking or not growing) in 73.5% of the anetumab ravtansine group and 68.3% of the vinorelbine group. Among those whose tumours did shrink, the response lasted a reported median of 7.4 months in the anetumab ravtansine group and 6.7 months in the vinorelbine group. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 35358455) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Mesothelioma Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with malignant pleural mesothelioma (a type of cancer affecting the lining of the lungs) that has been confirmed by a tissue sample, and your cancer produces high levels of a protein called mesothelin.
- Your cancer cannot be removed by surgery and has continued to grow or spread after receiving a first round of chemotherapy that included platinum-based drugs and pemetrexed.
- Your cancer can be measured on a scan to track whether treatment is working.
- You are generally able to carry out daily activities with little or no limitation (confirm with trial site for exact fitness level required).
- You are expected to live for at least 3 more months.
- Your blood, liver, and kidney functions are at acceptable levels.
- Your heart is pumping blood effectively, at 50% or above (or within your local hospital's normal range).
Who may not be able to join:
- You have already received more than one type of systemic (whole-body) cancer treatment.
- You have a condition affecting the surface of your eyes, or your doctor believes you may be at risk of developing one.
- Your cancer has spread to the brain, the membranes surrounding the brain, or anywhere else in the central nervous system.
- You have a history of or current signs of abnormal bleeding or difficulty with blood clotting.
- You currently have a significant active infection, whether bacterial, fungal, or viral (confirm with trial site for exact severity level).
- You have existing heart problems or conditions (confirm with trial site for specific details).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Bayer Study Director, Bayer
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
5 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Progression-free Survival (PFS), [95% CI]
Can't join this trial?
Data last synced from ClinicalTrials.gov: 29 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.